Economic evaluations of personalized medicine: existing challenges and current developments

References

• RedekopWKMladsiDThe faces of personalized medicine: a framework for understanding its meaning and scopeValue Health2013166S4S924034312
   PubMed Web of Science ®Google Scholar
• CooperNJSuttonAJAdesAEPaisleySJonesDRUse of evidence in economic decision models: practical issues and methodological challengesHealth Econ200716121277128618034447
   PubMed Web of Science ®Google Scholar
• ClaxtonKExploring uncertainty in cost-effectiveness analysisPharmacoeconomics200826978179818767898
   PubMed Web of Science ®Google Scholar
• ContiRVeenstraDLArmstrongKLeskoLJGrosseSDPersonalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research prioritiesMed Decis Making201030332834020086232
   PubMed Web of Science ®Google Scholar
• PhillipsKAVan BebberSLMeasuring the value of pharmacogenomicsNat Rev Drug Discov20054650050915915153
   PubMed Web of Science ®Google Scholar
• PhillipsKASakowskiJATrosmanJDouglasMPLiangSYNeumannPThe economic value of personalized medicine tests: what we know and what we need to knowGenet Med201416325125724232413
   PubMed Web of Science ®Google Scholar
• HatzMHSchremserKRogowskiWHIs individualized medicine more cost-effective? A systematic reviewPharmacoeconomics201432544345524574059
   PubMed Web of Science ®Google Scholar
• International Society for Pharmacoeconomics and Outcomes ResearchPharmacoeconomic Guidelines Around the World2015 Available from: http://www.ispor.org/peguidelines/index.aspAccessed February 26, 2015
   Google Scholar
• National Institute for Health and Care Excellence (NICE)Guide to the Methods of Technology Appraisal2013 Available from: http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdfAccessed May 1, 2014
   Google Scholar
• PhillipsKAVan BebberSLA systematic review of cost-effectiveness analyses of pharmacogenomic interventionsPharmacogenomics2004581139114915584880
   PubMed Web of Science ®Google Scholar
• VegterSJansenEPostmaMJBoersmaCEconomic evaluations of pharmacogenetic and genomic screening programs: update of the literatureDrug Dev Res2010718492501
   Web of Science ®Google Scholar
• VegterSBoersmaCRozenbaumMWilffertBNavisGPostmaMJPharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelinesPharmacoeconomics200826756958718563949
   PubMed Web of Science ®Google Scholar
• WongWBCarlsonJJTharianiRVeenstraDLCost effectiveness of pharmacogenomics: a critical and systematic reviewPharmacoeconomics201028111001101320936884
   PubMed Web of Science ®Google Scholar
• PhillipsKASakowskiJALiangSYPonceNAEconomic perspectives on personalized health care and preventionForum Health Econ Policy201316230
   Google Scholar
• GodmanBFinlaysonAECheemaPKPersonalizing health care: feasibility and future implicationsBMC Med20131117923941275
   PubMed Web of Science ®Google Scholar
• AnnemansLRedekopKPayneKCurrent methodological issues in the economic assessment of personalized medicineValue Health2013166S20S2624034308
   PubMed Web of Science ®Google Scholar
• BuchananJWordsworthSSchuhAIssues surrounding the health economic evaluation of genomic technologiesPharmacogenomics201314151833184724236483
   PubMed Web of Science ®Google Scholar
• CraigDMcDaidCFonsecaTStockCDuffySWoolacottNAre adverse effects incorporated in economic models? A survey of current practiceInt J Technol Assess Health Care201026332332920584362
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationPharmacogenomic Biomarkers in Drug Labeling2014 Available from: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htmAccessed May 1, 2014
   Google Scholar
• WilliamsIMMcIverSMooreDBryanSThe use of economic evaluations in NHS decision-making: a review and empirical investigationHealth Technol Assess20081271175
   Web of Science ®Google Scholar
• Centre for Reviews and DisseminationNHS Economic Evaluation Database Handbook2007 Available from: http://www.york.ac.uk/inst/crd/pdf/nhseed-handbook2007.pdfAccessed May 1, 2014
   Google Scholar
• HusereauDDrummondMPetrouSCHEERS Task ForceConsolidated health economic evaluation reporting standards (CHEERS) statementBMJ2013346f104923529982
   PubMed Web of Science ®Google Scholar
• IslerJAVesterqvistOEBurczynskiMEAnalytical validation of genotyping assays in the biomarker laboratoryPharmacogenomics20078435336817391073
   PubMed Web of Science ®Google Scholar
• WeissSTMcLeodHLFlockhartDACreating and evaluating genetic tests predictive of drug responseNat Rev Drug Discov20087756857418587383
   PubMed Web of Science ®Google Scholar
• FleemanNMartin SaboridoCPayneKThe clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic reviewHealth Technol Assess201115331102
   Web of Science ®Google Scholar
• FerrusiILMarshallDAKulinNALeighlNBPhillipsKALooking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analysesPer Med20096219321520668661
   PubMed Web of Science ®Google Scholar
• ElkinEBWeinsteinMCWinerEPKuntzKMSchnittSJWeeksJCHER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysisJ Clin Oncol200422585486314990641
   PubMed Web of Science ®Google Scholar
• BlankPRSchwenkglenksMMochHSzucsTDHuman epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategiesBreast Cancer Res Treat2010124249750720364309
   PubMed Web of Science ®Google Scholar
• ParkinsonBPearsonSAVineyREconomic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critiqueEur J Health Econ20141519311223436142
   PubMed Web of Science ®Google Scholar
• HicksJKSwenJJThornCFClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressantsClin Pharmacol Ther201393540240823486447
   PubMed Web of Science ®Google Scholar
• CrewsKRGaedigkADunnenbergerHMClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotypeClin Pharmacol Ther201291232132622205192
   PubMed Web of Science ®Google Scholar
• CraigDMcDaidCFonsecaTStockCDuffySWoolacottNAre adverse effects incorporated in economic models? An initial review of current practiceHealth Technol Assess2009136217197181
   Web of Science ®Google Scholar
• ShabaruddinFHChenLCElliottRAPayneKA systematic review of utility values for chemotherapy-related adverse eventsPharmacoeconomics201331427728823529208
   PubMed Web of Science ®Google Scholar
• NoordzijMTripepiGDekkerFWZoccaliCTanckMWJagerKJSample size calculations: basic principles and common pitfallsNephrol Dial Transplant20102551388139320067907
   PubMed Web of Science ®Google Scholar
• PirmohamedMBurnsideGErikssonNEU-PACT GroupA randomized trial of genotype-guided dosing of warfarinN Engl J Med2013369242294230324251363
   PubMed Web of Science ®Google Scholar
• KimmelSEFrenchBKasnerSEA pharmacogenetic versus a clinical algorithm for warfarin dosingN Engl J Med2013369242283229324251361
   PubMed Web of Science ®Google Scholar
• NewmanWGPayneKTrickerKTARGET Study Recruitment TeamA pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET studyPharmacogenomics201112681582621692613
   PubMed Web of Science ®Google Scholar
• SvenssonSMenkesDBLexchinJSurrogate outcomes in clinical trials: a cautionary taleJAMA Intern Med2013173861161223529157
   PubMed Web of Science ®Google Scholar
• SorichMJRowlandAWieseMDPharmacogenomic substudies of randomized controlled trials: consideration of safety outcomesTher Adv Drug Saf201452626625083262
   PubMedGoogle Scholar
• US National Institutes of HealthNational Cancer InstituteCommon Terminology Criteria for Adverse Events (CTCAE)2013 Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htmAccessed February 25, 2015
   Google Scholar
• FlemingTRPowersJHBiomarkers and surrogate endpoints in clinical trialsStat Med201231252973298422711298
   PubMed Web of Science ®Google Scholar
• FlemingTRDeMetsDLSurrogate end points in clinical trials: are we being misled?Ann Intern Med199612576056138815760
   PubMed Web of Science ®Google Scholar
• ShabaruddinFHEconomic Evaluation of the UGT1A1 Pharmacogenetic Test[dissertation]Manchester, UKThe University of Manchester2011
   Google Scholar
• SorichMJCooryMInterpreting the clinical utility of a pharmacogenomic marker based on observational association studiesPharmacogenomics J20141411524018622
   PubMed Web of Science ®Google Scholar
• CaudleKEKleinTEHoffmanJMIncorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development processCurr Drug Metab201415220921724479687
   PubMed Web of Science ®Google Scholar
• EpsteinRSMoyerTPAubertREWarfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study)J Am Coll Cardiol201055252804281220381283
   PubMed Web of Science ®Google Scholar
• JohnsonJAGongLWhirl-CarrilloMClinical Pharmacogenetics Implementation ConsortiumClinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingClin Pharmacol Ther201190462562921900891
   PubMed Web of Science ®Google Scholar
• AndersonJLHorneBDStevensSMA randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II)Circulation2012125161997200522431865
   PubMed Web of Science ®Google Scholar
• BurmesterJKBergRLYaleSHA randomized controlled trial of genotype-based Coumadin initiationGenet Med201113650951821423021
   PubMed Web of Science ®Google Scholar
• MayersCPanzarellaTTannockIFAnalysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinomaCancer200191122246225711413512
   PubMed Web of Science ®Google Scholar
• CameronDAMassieCKerrGLeonardRCModerate neutropenia with adjuvant CMF confers improved survival in early breast cancerBr J Cancer200389101837184214612889
   PubMed Web of Science ®Google Scholar
• TinkerAVSpeersCBarnettJOlivottoIAChiaSImpact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I-II breast cancersEcancermedicalscience200826322275960
   PubMedGoogle Scholar
• DrummondMFSculpherMTorranceGO’BrienBJStoddartGMethods for the Economic Evaluation of Health Care ProgrammesOxford, UKOxford University Press2005
   Google Scholar
• PayneKFish and chips all round? Regulation of DNA-based genetic diagnosticsHealth Econ200918111233123619821463
   PubMed Web of Science ®Google Scholar
• ThompsonAJNewmanWGElliottRARobertsSATrickerKPayneKThe cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprineValue Health2014171223324438714
   PubMed Web of Science ®Google Scholar
• GarberAMTunisSRDoes comparative-effectiveness research threaten personalized medicine?N Engl J Med2009360191925192719420360
   PubMed Web of Science ®Google Scholar
• SculpherMDrummondMBuxtonMThe iterative use of economic evaluation as part of the process of health technology assessmentJ Health Serv Res Policy199721263010180650
   PubMedGoogle Scholar
• DoumaKFKarsenbergKHummelMJBueno-de-MesquitaJMvan HartenWHMethodology of constructive technology assessment in health careInt J Technol Assess Health Care200723216216817493301
   PubMed Web of Science ®Google Scholar
• PhilipsZBojkeLSculpherMClaxtonKGolderSGood practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessmentPharmacoeconomics200624435537116605282
   PubMed Web of Science ®Google Scholar
• ShabaruddinFHElliottRAValleJWNewmanWGPayneKUnderstanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United KingdomBr J Cancer2010103331532320661248
   PubMed Web of Science ®Google Scholar
• SullivanWPayneKThe appropriate elicitation of expert opinion in economic models: making expert data fit for purposePharmacoeconomics201129645545921568356
   PubMed Web of Science ®Google Scholar
• LealJWordsworthSLegoodRBlairEEliciting expert opinion for economic models: an applied exampleValue Health200710319520317532812
   PubMed Web of Science ®Google Scholar
• O’HaganABuckCEDaneshkhahAUncertain Judgements: Eliciting Experts’ Probabilities (Statistics in Practice)ChichesterWiley2006
   Google Scholar
• SculpherMClaxtonKEstablishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty – when is there sufficient evidence?Value Health20058443344616091019
   PubMed Web of Science ®Google Scholar
• BeaulieuMde DenusSLachaineJSystematic review of pharmacoeconomic studies of pharmacogenomic testsPharmacogenomics201011111573159021121811
   PubMed Web of Science ®Google Scholar
• TowseAGarrisonLPJrEconomic incentives for evidence generation: promoting an efficient path to personalized medicineValue Health2013166 SupplS39S4324034311
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyReflection Paper on Methodological Issues Associated with Pharmacogenomic Biomarkers in Relation to Clinical Development and Patient Selection2011 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500108672.pdfAccessed February 23, 2015 EMA/446337/2011
   Google Scholar
• CoffeyCSLevinBClarkCOverview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshopClin Trials20129667168023250942
   PubMed Web of Science ®Google Scholar
• KairallaJACoffeyCSThomannMAMullerKEAdaptive trial designs: a review of barriers and opportunitiesTrials20121314522917111
   PubMed Web of Science ®Google Scholar
• NewmanWPayneKRemoving barriers to a clinical pharmacogenetics servicePer Med200855471480
   Web of Science ®Google Scholar
• McKinnonRAWardMBSorichMJA critical analysis of barriers to the clinical implementation of pharmacogenomicsTher Clin Risk Manag20073575175918473000
   PubMedGoogle Scholar
• US Food and Drug AdministrationDraft Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics2011 Available from: http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdfAccessed February 23, 2015
   Google Scholar
• PharmGKBDosing Guidelines – CPIC2015 Available from: http://www.pharmgkb.org/view/dosing-guidelines.do?source=CPIC#Accessed February 25, 2015
   Google Scholar
• ByronSKCrabbNGeorgeEMarlowMNewlandAThe Health Technology Assessment of companion diagnostics: experience of NICEClin Cancer Res20142061469147624634470
   PubMed Web of Science ®Google Scholar
• ClaxtonKPSculpherMJUsing value of information analysis to prioritise health research: some lessons from recent UK experiencePharmacoeconomics200624111055106817067191
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA Basics. What is the Approval Process for a New Prescription Drug?2014 Available from: http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194949.htmAccessed February 25, 2015
   Google Scholar
• Medicines and Healthcare Products Regulatory AgencyApply for a Licence to Market a Medicine in the UK Detailed Guidance2014 Available from: https://www.gov.uk/apply-for-a-licence-to-market-a-medicine-in-the-ukAccessed February 25, 2015
   Google Scholar
• European Medicines AgencyHuman Medicines: Regulatory Information2015 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/landing/human_medicines_regulatory.jsp&mid=Accessed February 25, 2015
   Google Scholar
• National Institute for Health and Care Excellence (NICE)Specification for Manufacturer/Sponsor Submission of Evidence2014 Available from: https://www.nice.org.uk/proxy/?sourceurl=http://www.nice.org.uk/aboutnice/howwework/devnicetech/specificationformanufacturersponsorsubmissionofevidence.jspAccessed February 25, 2015
   Google Scholar
• PayneKAnnemansLReflections on market access for personalized medicine: recommendations for EuropeValue Health2013166S32S3824034310
   PubMed Web of Science ®Google Scholar
• DavisJCFurstenthalLDesaiAAThe microeconomics of personalized medicine: today’s challenge and tomorrow’s promiseNat Rev Drug Discov20098427928619300459
   PubMed Web of Science ®Google Scholar
• FugelHJNuijtenMPostmaMStratified medicine and reimbursement issuesFront Pharmacol2012318123087645
   PubMed Web of Science ®Google Scholar
• DeverkaPAVernonJMcLeodHLEconomic opportunities and challenges for pharmacogenomicsAnnu Rev Pharmacol Toxicol20105042343720055709
   PubMed Web of Science ®Google Scholar
• FleemanNMcLeodCBagustAThe clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluationHealth Technol Assess2010143115720031087
   PubMed Web of Science ®Google Scholar
• WillkeRJCrownWDel AguilaMCzirakyMJKhanZMMiglioriRMelding regulatory, pharmaceutical industry, and US payer perspectives on improving approaches to heterogeneity of treatment effect in research and practiceValue Health2013166 SupplS10S1524034306
   PubMed Web of Science ®Google Scholar
• FruehFWRegulation, reimbursement, and the long road of implementation of personalized medicine – a perspective from the United StatesValue Health2013166S27S3124034309
   PubMed Web of Science ®Google Scholar
• Medical Research CouncilStratified Medicine2015 Available from: http://www.mrc.ac.uk/research/initiatives/stratified-medicine/Accessed February 26, 2015
   Google Scholar